Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capsaicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 known ✓ | Q8NER1 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zucapsaicin SCHEMBL41210 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Zucapsaicin SCHEMBL29787104 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL8085 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL8086 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL29370401 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL10956845 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL6065297 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL6905200 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| Capsaicin SCHEMBL29473408 | 1.00 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 | |
| SCHEMBL16309566 | 0.99 | TRPV1 (0.98) | TRPV1CYP1A2CYP3A4ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050181022-A1 | Confectionary products including agent for controlling weight | WM. WRIGLEY JR. COMPANY | 2005-08-18 | — | — | US | claimed |
| CN-117572575-A | Rat-proof protective sleeve for electric power optical cable and preparation method and device thereof | 云南电网有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| US-20090110796-A1 | AROMATIC NEOMENTHYLAMIDES AS FLAVORING SUBSTANCES | SYMRISE GMBH & CO. KG (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2006060505-A2 | CAPSAICIN NUTRITIONAL SUPPLEMENT | DACANAY RHODEL G (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20050181022-A1 | Confectionary products including agent for controlling weight | WM. WRIGLEY JR. COMPANY | 2005-08-18 | — | — | US | disclosed |
| US-6689399-B1 | CAPSACINOID IN CONJUNCTION WITH GLUCOSAMINE AT A HIGH CONCENTRATION, SYNERGISTIC; PROLONGED PAIN RELIEF EFFECT IS ACHIEVED WITHOUT INTENSE BURNING OR STINGING SENSATION USUALLY ASSOCIATED WITH TOPICAL CAPSAICIN | AVENTIS PHARMACEUTICALS INC. | 2004-02-10 | — | — | US | disclosed |
| US-4546112-A | APPLYING CAPSAICIN OR ITS SALTS | THE PROCTER & GAMBLE COMPANY (US) | 1985-10-08 | — | — | US | disclosed |
| EP-0068591-B1 | NOVEL SULFONAMIDE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1985-09-25 | — | — | EP | disclosed |
| US-4401663-A | ANALGESICS, ANTI-IRRITANTS, DEPILATORIES | THE PROCTER & GAMBLE COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110796-A1 | AROMATIC NEOMENTHYLAMIDES AS FLAVORING SUBSTANCES | AOC3, NPR3, AOC2 | TRPV1 716/4885CYP1A2 425/4885CYP3A4 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.